| abstract |
Disclosed herein are compounds that form covalent bonds with bruton tyrosine kinase (Btk). Also disclosed herein are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are described. Also disclosed are pharmaceutical compositions comprising such compounds. Methods of using Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, different immune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions are disclosed. |